Ecor1 Capital Increased Its Dicerna Pharmaceuticals (DRNA) Position by $34.91 Million as Shares Rose; Gilead Sciences Gild Us (GILD) Shareholder Tb Alternative Assets LTD Boosted Its Position

April 17, 2018 - By Vivian Park

Gilead Sciences, Inc. (NASDAQ:GILD) Logo

Tb Alternative Assets Ltd increased its stake in Gilead Sciences Inc Gild Us (GILD) by 453.47% based on its latest 2017Q4 regulatory filing with the SEC. Tb Alternative Assets Ltd bought 91,600 shares as the company’s stock rose 1.93% while stock markets declined. The institutional investor held 111,800 shares of the health care company at the end of 2017Q4, valued at $8.01 million, up from 20,200 at the end of the previous reported quarter. Tb Alternative Assets Ltd who had been investing in Gilead Sciences Inc Gild Us for a number of months, seems to be bullish on the $98.64 billion market cap company. The stock increased 1.29% or $0.96 during the last trading session, reaching $75.65. About 1.93 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since April 17, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.

Ecor1 Capital Llc increased its stake in Dicerna Pharmaceuticals Inc (DRNA) by 404.86% based on its latest 2017Q4 regulatory filing with the SEC. Ecor1 Capital Llc bought 3.88 million shares as the company’s stock rose 19.47% while stock markets declined. The institutional investor held 4.84M shares of the health care company at the end of 2017Q4, valued at $43.67M, up from 957,992 at the end of the previous reported quarter. Ecor1 Capital Llc who had been investing in Dicerna Pharmaceuticals Inc for a number of months, seems to be bullish on the $550.28 million market cap company. The stock increased 3.10% or $0.32 during the last trading session, reaching $10.63. About 78,508 shares traded. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has risen 274.53% since April 17, 2017 and is uptrending. It has outperformed by 262.98% the S&P500.

Investors sentiment increased to 3 in 2017 Q4. Its up 2.21, from 0.79 in 2017Q3. It increased, as 6 investors sold DRNA shares while 5 reduced holdings. 18 funds opened positions while 15 raised stakes. 29.10 million shares or 180.62% more from 10.37 million shares in 2017Q3 were reported. Palo Alto Invsts Ltd Company accumulated 0.19% or 500,913 shares. Camber Mgmt Limited Liability holds 0.44% or 1.00 million shares in its portfolio. Bridgeway Capital Mngmt Inc reported 149,900 shares. Morgan Stanley, a New York-based fund reported 1,874 shares. 117,321 are held by Blackrock. Deutsche Commercial Bank Ag holds 0% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 168,400 shares. 41,000 are owned by California Public Employees Retirement Sys. Endurant Capital Limited Partnership stated it has 0.05% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Emerald Mutual Fund Advisers Trust has invested 0.2% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Goldman Sachs Group Inc Incorporated Inc reported 194,198 shares or 0% of all its holdings. Adage Cap Gp Lc has invested 0.04% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Emerald Advisers Pa reported 29,504 shares. Northern Trust Corporation invested in 36,282 shares or 0% of the stock. State Street reported 10,321 shares. Cormorant Asset Limited has 3.46% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA).

Since December 18, 2017, it had 1 insider purchase, and 1 sale for $1.98 million activity. Weissman James B sold 1,035 shares worth $13,455.

Among 9 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 4 have Buy rating, 0 Sell and 5 Hold. Therefore 44% are positive. Dicerna Pharmaceuticals had 25 analyst reports since August 7, 2015 according to SRatingsIntel. The stock has “Neutral” rating by H.C. Wainwright on Friday, March 23. The firm has “Hold” rating given on Friday, August 11 by Chardan Capital Markets. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Buy” rating given on Friday, March 9 by Stifel Nicolaus. Stifel Nicolaus maintained it with “Buy” rating and $10.0 target in Thursday, November 2 report. The firm earned “Neutral” rating on Thursday, June 30 by Chardan Capital Markets. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Hold” rating given on Tuesday, March 27 by FBR Capital. Cowen & Co initiated the stock with “Buy” rating in Wednesday, April 11 report. Chardan Capital Markets maintained the stock with “Neutral” rating in Monday, August 15 report. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Buy” rating given on Wednesday, August 16 by Cowen & Co. The rating was initiated by Cowen & Co with “Outperform” on Tuesday, September 8.

Tb Alternative Assets Ltd, which manages about $269.07 million US Long portfolio, decreased its stake in Spn Adr Bzun Us by 292,100 shares to 1.08 million shares, valued at $33.95M in 2017Q4, according to the filing. It also reduced its holding in New Oriental Educatio (NYSE:EDU) by 8,978 shares in the quarter, leaving it with 175,800 shares, and cut its stake in Macy’s Inc M Us (NYSE:M).

Investors sentiment decreased to 0.8 in Q4 2017. Its down 0.23, from 1.03 in 2017Q3. It dived, as 95 investors sold GILD shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported. Investec Asset Mngmt has 0.03% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Green Valley Limited Co owns 210,081 shares or 0.72% of their US portfolio. Holderness Invs has invested 0.14% in Gilead Sciences, Inc. (NASDAQ:GILD). Ing Groep Nv stated it has 0.01% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Ashfield Cap Partners Lc has 2,820 shares. Penn Davis Mcfarland Inc, Texas-based fund reported 167,555 shares. Clear Harbor Asset Mngmt Ltd holds 0.15% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 11,195 shares. M Hldgs Secs Incorporated invested 0.26% in Gilead Sciences, Inc. (NASDAQ:GILD). Pillar Pacific Cap Mngmt Ltd accumulated 103,919 shares or 0.91% of the stock. Contravisory Investment Mgmt invested in 0.01% or 339 shares. 70,728 were reported by Brookstone Cap Mngmt. Hamilton Point Invest Advsr Ltd Liability Com accumulated 22,268 shares or 0.83% of the stock. Banque Pictet And Cie Sa reported 136,397 shares. Moreover, Jlb & Associates has 1.86% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Portland Global Advisors Limited Liability Corporation holds 0.09% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 3,478 shares.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences had 126 analyst reports since July 29, 2015 according to SRatingsIntel. As per Wednesday, February 7, the company rating was maintained by RBC Capital Markets. Credit Suisse downgraded the stock to “Neutral” rating in Wednesday, December 20 report. The rating was initiated by William Blair with “Buy” on Thursday, August 31. The firm has “Hold” rating by Credit Suisse given on Wednesday, January 3. The firm has “Overweight” rating by Piper Jaffray given on Friday, July 24. The rating was downgraded by Argus Research to “Hold” on Monday, November 13. The stock has “Hold” rating by Oppenheimer on Wednesday, October 4. The company was upgraded on Friday, January 15 by Bank of America. The rating was maintained by Mizuho on Thursday, September 28 with “Buy”. The rating was downgraded by Argus Research to “Hold” on Friday, July 29.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>